Open AccessRole of octreotide in small bowel bleeding
Author(s) -
Anwar Khedr,
Esraa Mahmoud,
Noura Attallah,
Mikael Mir,
Sydney Boike,
Ibtisam Rauf,
Abbas B Jama,
Hisham Mushtaq,
Salim Surani,
Syed Anjum Khan
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i26.9192
Subject(s) - medicine , octreotide , gastrointestinal bleeding , splanchnic , somatostatin , angiodysplasia , gastroenterology , intensive care medicine , blood flow
Gastrointestinal bleeding accounts for a drastic negative impact on the quality of the patients' lives as it requires multiple diagnostic and therapeutic interventions to identify the source of the bleeding. Small bowel bleeding is the least common cause of gastrointestinal bleeding. However, it is responsible for the majority of complaints from patients with persisting or recurring bleeding where the primary source of bleeding cannot be identified despite investigation. A somatostatin analog known as octreotide is among the medical treatment modalities currently used to manage small bowel bleeding. This medication helps control symptoms of gastrointestinal bleeding by augmenting platelet aggregation, decreasing splanchnic blood flow, and antagonizing angiogenesis. In this review article, we will highlight the clinical efficacy of octreotide in small bowel bleeding and its subsequent effect on morbidity and mortality.